Announcements Trials
Browse Landscape

Phase

Phase NA 1

Status

Recruiting 1

Sponsor Class

OTHER 29INDUSTRY 6OTHER_GOV 1

Study Type

Interventional 1

Sponsor

Cancer Type

Thoracic 1CNS 1

Conditions

Meningeal Carcinomatosis 1Carcinoma, Non-Small-Cell Lung 1

Interventions

Pemetrexed 6Cisplatin 6Nivolumab 5Gemcitabine 5Drug Therapy 5Radiotherapy 4Docetaxel 4pembrolizumab 3Platinum Compounds 3Immune Checkpoint Inhibitors 3Endostatins 3Carboplatin 3tislelizumab 2endostar protein 2durvalumab 2camrelizumab 2Thalidomide 2Paclitaxel 2Oxaliplatin 2Irinotecan 2Gefitinib 2Erlotinib Hydrochloride 2Bevacizumab 2Afatinib 2trilaciclib 1toripalimab 1titanium silicide 1osimertinib 1olaparib 1lorlatinib 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
OTHER_GOV × Carcinoma, Non-Small-Cell Lung × aflutinib × Clear all
NCT06643000 2025-03-06

Evaluating High-dose Furmonertinib with Bevacizumab and Pemetrexed for EGFRm NSCLC with Leptomeningeal Metastasis

Henan Cancer Hospital

Phase NA Recruiting
60 enrolled
CNSThoracic

Carcinoma, Non-Small-Cell Lung, Meningeal Carcinomatosis

Data powered by HemOnc (CC BY 4.0) Colophon âš¡